Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Werdan, S. Perings, R. Köster, M. Kelm, T. Meinertz, G. Stöckl, U. Müller-Werdan (2016)
Effectiveness of Ivabradine Treatment in Different Subpopulations with Stable Angina in Clinical Practice: A Pooled Analysis of Observational StudiesCardiology, 135
P. Steg, R. Ferrari, I. Ford, N. Greenlaw, J. Tardif, M. Tendera, H. Abergel, K. Fox (2012)
Heart Rate and Use of Beta-Blockers in Stable Outpatients with Coronary Artery DiseasePLoS ONE, 7
R. Sy, S. Freedman (2011)
Beta-Blocker Dose Up-Titration or Addition of Ivabradine in Stable Angina: More is Not Necessarily BetterCardiovascular Drugs and Therapy, 25
C. Daly, F. Clemens, J. Sendón, L. Tavazzi, E. Boersma, N. Danchin, F. Delahaye, A. Gitt, D. Julian, D. Mulcahy, W. Rużyłło, K. Thygesen, F. Verheugt, K. Fox (2010)
Inadequate control of heart rate in patients with stable angina: results from the European Heart SurveyPostgraduate Medical Journal, 86
S. Bangalore, G. Kamalakkannan, S. Parkar, F. Messerli (2007)
Fixed-dose combinations improve medication compliance: a meta-analysis.The American journal of medicine, 120 8
D. Morisky, L. Green, D. Levine (1986)
Concurrent and Predictive Validity of a Self-reported Measure of Medication AdherenceMedical Care, 24
S. Perings, G. Stöckl, M. Kelm (2016)
Effectiveness and Tolerability of Ivabradine with or Without Concomitant Beta-Blocker Therapy in Patients with Chronic Stable Angina in Routine Clinical PracticeAdvances in Therapy, 33
J. Borer, K. Fox, P. Jaillon, G. Lerebours (2003)
Antianginal and Antiischemic Effects of Ivabradine, an If Inhibitor, in Stable Angina: A Randomized, Double-Blind, Multicentered, Placebo-Controlled TrialCirculation: Journal of the American Heart Association, 107
K. Werdan, H. Ebelt, S. Nuding, Florian Höpfner, G. Stöckl, U. Müller-Werdan (2015)
Ivabradine in Combination with Metoprolol Improves Symptoms and Quality of Life in Patients with Stable Angina Pectoris: A post hoc Analysis from the ADDITIONS TrialCardiology, 133
L. López‐Bescós, S. Filipová, R. Martos (2007)
Long-Term Safety and Efficacy of Ivabradine in Patients with Chronic Stable AnginaCardiology, 108
E. Amosova, E. Andrejev, I. Zaderey, U. Rudenko, C. Ceconi, Roberto Ferrari (2011)
Efficacy of Ivabradine in Combination with Beta-Blocker Versus Uptitration of Beta-Blocker in Patients with Stable AnginaCardiovascular Drugs and Therapy, 25
JM Gardin SD Fihn (2012)
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic SurgeonsCirculation, 126
K. Werdan, H. Ebelt, S. Nuding, Florian Höpfner, G. Hack, U. Müller-Werdan (2012)
Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS studyClinical Research in Cardiology, 101
E. Tagliamonte, T. Cirillo, F. Rigo, C. Astarita, A. Coppola, C. Romanò, N. Capuano (2015)
Ivabradine and Bisoprolol on Doppler-derived Coronary Flow Velocity Reserve in Patients with Stable Coronary Artery Disease: Beyond the Heart RateAdvances in Therapy, 32
S. Fihn, J. Gardin, J. Abrams, K. Berra, J. Blankenship, Apostolos Dallas, P. Douglas, J. Foody, T. Gerber, A. Hinderliter, S. King, P. Kligfield, H. Krumholz, Raymond Kwong, M. Lim, Jane Linderbaum, M. Mack, M. Munger, R. Prager, J. Sabik, L. Shaw, Joanna Sikkema, Craig Smith, Sidney Smith, J. Spertus, Sankey Williams (2012)
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of PhysiJournal of the American College of Cardiology, 60 24
Y. Tsuchiya, T. Muramatsu, T. Masaoka, S. Hashimoto, M. Shimono (2017)
Effect of
C. Vitale, M. Fini, I. Spoletini, M. Lainščak, P. Seferovic, G. Rosano (2017)
Under-representation of elderly and women in clinical trials.International journal of cardiology, 232
G. Montalescot, G. Rangé, L. Belle, C. Pouillot, Z. Boueri, G. Cayla, E. Belle, J. Silvain, E. Vicaut, J. Collet (2013)
Platelet function testing to adjust antiplatelet therapy for elective coronary stenting: a landmark analysis of the ARCTIC trialEuropean Heart Journal, 34
V. Fung, Jie Huang, R. Brand, J. Newhouse, J. Hsu (2007)
Hypertension treatment in a medicare population: adherence and systolic blood pressure control.Clinical therapeutics, 29 5
D. DiFrancesco, J. Camm (2004)
Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.Drugs, 64 16
F. Mangiacapra, I. Colaiori, E. Ricottini, F. Balducci, A. Creta, C. Demartini, G. Minotti, G. Sciascio (2016)
Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL studyClinical Research in Cardiology, 106
Stephan Fihn, J. Gardin, Jonathan Abrams, Kathleen Berra, James Blankenship, Apostolos Dallas, P. Douglas, J. Foody, Thomas Gerber, A. Hinderliter, Spencer King, Paul Kligfield, H. Krumholz, Raymond Kwong, Michael Lim, Jane Linderbaum, Michael Mack, Mark Munger, Richard Prager, J. Sabik, Leslee Shaw, Joanna Sikkema, Craig Smith, Sidney Smith, J. Spertus, Sankey Williams (2012)
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American AssJournal of the American College of Cardiology, 60 24
C. Thollon, J. Vilaine (2010)
I(f) inhibition in cardiovascular diseases.Advances in pharmacology, 59
N. Muszbek, D. Brixner, Á. Benedict, A. Keskinaslan, Z. Khan (2008)
The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature reviewInternational Journal of Clinical Practice, 62
P. Camici, S. Gloekler, B. Lévy, E. Skalidis, E. Tagliamonte, P. Vardas, G. Heusch (2016)
Ivabradine in chronic stable angina: Effects by and beyond heart rate reduction.International journal of cardiology, 215
G. Heusch (2008)
Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agentsBritish Journal of Pharmacology, 153
Sonali Kulkarni, K. Alexander, B. Lytle, G. Heiss, E. Peterson (2006)
Long-term adherence with cardiovascular drug regimens.American heart journal, 151 1
S. Gloekler, T. Traupe, M. Stoller, D. Schild, H. Steck, A. Khattab, R. Vogel, C. Seiler (2013)
The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery diseaseHeart, 100
D. DiFrancesco (2005)
Cardiac pacemaker /f current and its inhibition by heart rate-reducing agentsCurrent Medical Research and Opinion, 21
R. Köster, J. Kaehler, T. Meinertz (2009)
Treatment of stable angina pectoris by ivabradine in every day practice: the REDUCTION study.American heart journal, 158 4
J. Tardif, P. Ponikowski, T. Kahan (2009)
Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trialEuropean Heart Journal, 30
F. Wiest, C. Bryson, M. Burman, M. McDonell, Jorja Henikoff, S. Fihn (2004)
Suboptimal pharmacotherapeutic management of chronic stable angina in the primary care setting.The American journal of medicine, 117 4
G. Montalescot, U. Sechtem, S. Achenbach, F. Andreotti, C. Arden, A. Budaj, R. Bugiardini, F. Crea, T. Cuisset, C. Mario, J. Ferreira, B. Gersh, A. Gitt, J. Hulot, N. Marx, L. Opie, M. Pfisterer, E. Prescott, F. Ruschitzka, M. Sabaté, R. Senior, D. Taggart, E. Wall, C. Vrints, J. Zamorano, H. Baumgartner, Jeroen Bax, H. Bueno, V. Dean, C. Deaton, Ç. Erol, R. Fagard, R. Ferrari, D. Hasdai, A. Hoes, P. Kirchhof, J. Knuuti, P. Kolh, P. Lancellotti, A. Linhart, P. Nihoyannopoulos, M. Piepoli, P. Ponikowski, P. Sirnes, J. Tamargo, M. Tendera, A. Torbicki, W. Wijns, S. Windecker, M. Valgimigli, M. Claeys, N. Donner‐Banzhoff, Herbert Frank, C. Funck-Brentano, O. Gaemperli, J. González-Juanatey, M. Hamilos, S. Husted, S. James, K. Kervinen, S. Kristensen, A. Maggioni, A. Pries, F. Romeo, L. Rydén, M. Simoons, P. Steg, A. Timmis, A. Yıldırır (2013)
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.European heart journal, 34 38
J. Dillinger, V. Maher, C. Vitale, P. Henry, D. Logeart, S. Silberman, Guillaume Allée, B. Lévy (2015)
Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery DiseaseHypertension, 66
W. Rużyłło, M. Tendera, I. Ford, K. Fox (2012)
Antianginal Efficacy and Safety of Ivabradine Compared with Amlodipine in Patients with Stable Effort Angina PectorisDrugs, 67
U. Sechtem, A. Budaj, J. Ferreira, B. Gersh (2013)
ESC guidelines on the management of stable coronary artery disease — addenda The Task Force on the management of stable coronary artery disease of the European Society of Cardiology
N. Choudhry, M. Fischer, J. Avorn, J. Liberman, S. Schneeweiss, J. Pakes, T. Brennan, W. Shrank (2011)
The implications of therapeutic complexity on adherence to cardiovascular medications.Archives of internal medicine, 171 9
M. Tendera, K. Fox, R. Ferrari, I. Ford, N. Greenlaw, H. Abergel, H. Abergel, C. Macarie, J. Tardif, P. Vardas, J. Zamorano, P. Steg (2014)
Inadequate heart rate control despite widespread use of beta-blockers in outpatients with stable CAD: findings from the international prospective CLARIFY registry.International journal of cardiology, 176 1
CL Bryson FC Wiest (2004)
Suboptimal pharmacotherapeutic management of chronic stable angina in the primary care settingAm J Med, 117
B. Patel, R. Leslie, P. Thiebaud, M. Nichol, Simon Tang, H. Solomon, D. Honda, J. Foody (2008)
Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimenVascular Health and Risk Management, 4
J. Tardif, I. Ford, M. Tendera, M. Bourassa, K. Fox (2005)
Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.European heart journal, 26 23
Abstract Introduction In this prospective, multicenter, observational cohort study, the effectiveness and tolerability of the first fixed-dose combination (FDC) formulation of the selective heart rate reducing agent ivabradine and the beta-blocker metoprolol was evaluated in stable angina pectoris (AP) patients in a clinical practice setting. Methods Stable AP outpatients received a FDC of ivabradine and metoprolol (b.i.d.) for 4 months, in addition to cardiovascular standard therapy. Resting heart rate (HR), number of angina attacks, short-acting nitrate consumption, severity of symptoms (assessed by patient judgment and documented by CCS score) and tolerability were documented. Medication adherence was assessed by a modified four-item Morisky questionnaire. Descriptive statistics were performed on all data. Results A total of 747 stable AP patients (mean age, 66.4 years, 62% male, 50% and 31% with previous PCI and myocardial infarction, respectively) were included. Apart from ivabradine and beta-blockers as free combination, most frequently used concomitant standard medications at baseline were aspirin (68%), statins (71%), ACEI/AT1-blockers (76%), diuretics (35%), and calcium antagonists (15%). Highly prevalent comorbidities were hypertension (86%), hyperlipidemia (65%), and diabetes (35%). After 4 months, switch to treatment with the FDC was associated with a significant reduction in mean HR by 10 bpm. Proportion of patients with ≥ 1 angina attacks/week decreased from 38 to 7%. Patients in CCS class 1 increased (25 to 63%), while they decreased in CCS class 3 (19 to 5%). Medication adherence was also significantly improved (p < 0.001 for all changes from baseline). Mostly mild adverse events were documented in 5.4% of patients. Conclusions In these stable AP patients in a real-life setting, treatment with a FDC of ivabradine and metoprolol was associated with reduced HR and angina symptoms, while exercise capacity (CCS score) was improved. These effects may be mainly mediated by the increased medication adherence of patients observed with use of the FDC formulation. Funding Servier Trial registration number ISRCTN51906157
Cardiology and Therapy – Springer Journals
Published: Dec 1, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.